OptimizeRx Corp — Director's Dealing 2022

Feb 15, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OptimizeRx Corp (OPRX)
CIK: 0001448431
Period of Report: 2022-02-11

Reporting Person: Odence-Ford Marion (General Counsel and CCO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-11	Common Stock	M	4000	—	Acquired	4000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-11	Restricted Stock Units	$	M	4000	Disposed		Common Stock (4000)	Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: On February 11, 2021, the reporting person was granted 20,000 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date